CA2039420C - Treatment of cataract with 15-keto-prostaglandin compounds - Google Patents

Treatment of cataract with 15-keto-prostaglandin compounds

Info

Publication number
CA2039420C
CA2039420C CA002039420A CA2039420A CA2039420C CA 2039420 C CA2039420 C CA 2039420C CA 002039420 A CA002039420 A CA 002039420A CA 2039420 A CA2039420 A CA 2039420A CA 2039420 C CA2039420 C CA 2039420C
Authority
CA
Canada
Prior art keywords
compound
alkyl
keto
dihydro
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002039420A
Other languages
English (en)
French (fr)
Other versions
CA2039420A1 (en
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of CA2039420A1 publication Critical patent/CA2039420A1/en
Application granted granted Critical
Publication of CA2039420C publication Critical patent/CA2039420C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002039420A 1990-04-04 1991-03-28 Treatment of cataract with 15-keto-prostaglandin compounds Expired - Lifetime CA2039420C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9089590 1990-04-04
JP90895/1990 1990-04-04
JP22164690 1990-08-22
JP221646/1990 1990-08-22
JP2931091 1991-01-29
JP29310/1991 1991-01-29

Publications (2)

Publication Number Publication Date
CA2039420A1 CA2039420A1 (en) 1991-10-05
CA2039420C true CA2039420C (en) 1996-12-10

Family

ID=27286510

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002039420A Expired - Lifetime CA2039420C (en) 1990-04-04 1991-03-28 Treatment of cataract with 15-keto-prostaglandin compounds

Country Status (11)

Country Link
US (2) US5212324A (en:Method)
EP (1) EP0453127B1 (en:Method)
KR (1) KR970005172B1 (en:Method)
AT (1) ATE169219T1 (en:Method)
AU (1) AU644148B2 (en:Method)
CA (1) CA2039420C (en:Method)
DE (1) DE69129921T2 (en:Method)
DK (1) DK0453127T3 (en:Method)
ES (1) ES2119762T3 (en:Method)
GR (1) GR3027666T3 (en:Method)
TW (2) TW224942B (en:Method)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205508B (en:Method) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
SE9303627D0 (sv) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for prevention of cataract
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
SE9403160D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab Method and means for prevention and treatment of secondary cataract
US6242485B1 (en) * 1996-06-10 2001-06-05 R-Tech Ueno Endothelin antagonist
BR9811774A (pt) * 1997-09-09 2000-08-29 Procter & Gamble Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp
SK3382000A3 (en) * 1997-09-09 2000-10-09 Procter & Gamble A compound having structure of aromatic substituted prostaglandins and its use for the treatment of bone disorders
EP0978284B1 (en) * 1997-11-28 2008-07-23 Sucampo AG Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
AU4114301A (en) * 2000-03-16 2001-09-24 Sucampo Ag Treatment of ocular hypertension and glaucoma
CA2403086C (en) 2000-03-24 2010-08-17 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
JP4183943B2 (ja) 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2003018025A1 (en) * 2001-08-23 2003-03-06 Sucampo Ag Method and composition for treatment of ocular hypertension and glaucoma
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
AU2003292556B2 (en) 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
KR20120005052A (ko) 2003-08-21 2012-01-13 수캄포 아게 안과용 조성물
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7321057B2 (en) * 2004-08-02 2008-01-22 R-Tech Ueno, Ltd. Method for manufacturing prostaglandin analogue
AU2006209072B2 (en) 2005-01-27 2011-02-24 Sucampo Ag Method and composition for treating central nervous system disorders
US8143316B2 (en) * 2005-03-04 2012-03-27 Sucampo Ag Method for treating peripheral vascular diseases
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
CA2637275C (en) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
RU2420291C3 (ru) * 2006-01-24 2020-07-21 Р-Тек Уено, Лтд. Состав в мягкой желатиновой капсуле
CA2645311C (en) 2006-03-13 2014-11-18 R-Tech Ueno, Ltd. Aqueous composition comprising 15-keto-prostaglandin for ophthalmic use
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US8569279B2 (en) * 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2012137987A1 (en) 2011-04-07 2012-10-11 Sucampo Ag Method for treating asthenopia
AU2012293157A1 (en) 2011-08-05 2014-03-13 Sucampo Ag Method for treating schizophrenia
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
US20150057351A1 (en) 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
US20170020890A1 (en) 2015-06-19 2017-01-26 Sucampo Ag Pharmaceutical composition comprising fatty acid derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505386A (en) * 1965-12-29 1970-04-07 Upjohn Co Compounds related to prostaglandins
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
ATE108330T1 (de) * 1987-09-18 1994-07-15 R Tech Ueno Ltd Hypotensive okulare mittel.
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
DE68906193T2 (de) * 1988-05-23 1993-08-05 Ueno Seiyaku Oyo Kenkyujo Kk Hypersphyxia verursachende zusammensetzung.
AU604156B2 (en) * 1988-09-14 1990-12-06 R-Tech Ueno, Ltd. Prostaglandins of the F series
EP0366279B1 (en) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Ocular hypotensive agents
TW205508B (en:Method) * 1990-08-02 1993-05-11 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo

Also Published As

Publication number Publication date
AU7404791A (en) 1991-10-10
DE69129921T2 (de) 1999-01-14
DK0453127T3 (da) 1998-10-26
DE69129921D1 (de) 1998-09-10
CA2039420A1 (en) 1991-10-05
US5212324A (en) 1993-05-18
TW249226B (en:Method) 1995-06-11
AU644148B2 (en) 1993-12-02
KR910018027A (ko) 1991-11-30
TW224942B (en:Method) 1994-06-11
ES2119762T3 (es) 1998-10-16
KR970005172B1 (ko) 1997-04-14
ATE169219T1 (de) 1998-08-15
EP0453127A3 (en) 1992-12-09
EP0453127A2 (en) 1991-10-23
GR3027666T3 (en) 1998-11-30
EP0453127B1 (en) 1998-08-05
US5686487A (en) 1997-11-11

Similar Documents

Publication Publication Date Title
EP0453127B1 (en) Treatment of cataract with 15-keto-prostaglandin compounds
US5432174A (en) Treatment of ocular hypertension
EP0503887B1 (en) Promotion of wound-healing with 15-keto-prostaglandin compounds
US5164415A (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
EP0467564B1 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
EP0342003B1 (en) Use of 15-ketoprostaglandin e or f compounds for uterine contraction
EP0458588A1 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
KR0127297B1 (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료
US5397797A (en) Treatment of ocular hypertension with an ocular synergistic combination
CA2042937C (en) Treatment of ocular hypertension with a synergistic combination
EP0430551B1 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
EP0469782B1 (en) Treatment of cataract with prostacyclin compounds
EP0458587A1 (en) Synergistic combination for ophthalmic use
US5175189A (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
EP0410646B1 (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
WO2001068072A2 (en) Composition for use in treatment of ocular hypertension and glaucoma

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry